STOCK TITAN

ANI Pharmaceuticals to Present at Upcoming December Investor Conference

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

ANI Pharmaceuticals (ANIP) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 1, 2026. President and CEO Nikhil Lalwani and other executives will join the chat at 12:30 p.m. ET. Live and archived webcasts will be available in the Events and Presentations area of the company’s Investors section.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

PRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in a fireside chat at the following upcoming investor conference:

EventPiper Sandler Healthcare Conference
DateTuesday, December 1, 2026
Time12:30 p.m. ET
WebcastClick here
  

The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.


Keep reading